Posted by Michael Wonder on 31 Dec 2024
Chimerix submits dordaviprone new drug application for accelerated approval to US FDA for patients with recurrent H3 K27M mutant diffuse glioma
30 December 2024 - Secures access of up to $30 million to support potential launch through Silicon Valley Bank credit facility.
Chimerix today confirms that the Company has submitted a new drug application with the US FDA seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma in the US.
